News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 73–108
- Matches
- 53753
- Sources here
- 22
- Companies here
- 43
Search results
Stored financial headlines
Active search
53753 matching headlines
Ticker or company: STMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
AstraZeneca halts eVOLVE-Lung02 trial of volrustomig combo
[A big sign with AstraZeneca logotype outside the entrance.] Wirestock * AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]) is discontinuing its eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer after an independent committee concluded the drug was unlikely to meet either primary …
AZN
main company
AZN1N
main company
AZN
main company
A1ZN34
main company
AZN
main company
AZN
main company
Sharemaestro market context
Price below Trend Line
52 weeks +14.4%
Ross Stores (ROST) Stock Looks Stretched On Earnings Yet Strong On Returns
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Ross Stores stock has delivered a strong run over the last few years, yet …
Sharemaestro market context Trend signal active 52 weeks +98.1%Is Toast (TOST) Above Fair Value After New Partnership Wins?
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Toast stock has delivered a strong 60.1% gain over the past three years. However, the latest valuation checks suggest the shares are not a …
Sharemaestro market context Trend signal started 52 weeks -30.1% · Next-week setup negative 27.0%What Does Western Digital (WDC) Signal With A $93.9 Billion Spin Off Backlog?
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Western Digital (NasdaqGS:WDC) spin off SanDisk outlined a US$93.9b customer backlog at its recent …
Sharemaestro market context Trend signal active 52 weeks +507.6%What Is Behind The Latest Camden Property Trust (CPT) Update?
Camden Property Trust (CPT) has filed a shelf registration for up to 7,250,000 common shares, valued at approximately US$802.865 million, linked to an Employee Stock Ownership Plan. Despite recent short-term share price dips, the company shows steady longer-term returns and trades below analyst targets …
CPT
main company
Sharemaestro market context
Trend signal active
52 weeks +3.9%
Fervo Energy Company (FRVO) loses nearly a quarter in weekly renewable-utilities slide
The geothermal stock’s latest move keeps pressure on the tape, with elevated activity but weak technical confirmation.
FRVO
main company
Sharemaestro market context
Stored weekly price path
14 weeks -51.9% · Next-week setup negative 17.3%
Westlake Corporation declares $0.533 dividend
* Westlake Corporation (WLK [https://seekingalpha.com/symbol/WLK]) declares $0.533/share quarterly dividend [https://seekingalpha.com/pr/20620238-westlake-corporation-declares-quarterly-dividend], 0.6% increase from prior dividend of $0.530. * Forward yield [https://seekingalpha.com/symbol/WLK/dividends/yield?source=news_bullet] 2.68% * Payable Sept. 10; for shareholders of record Aug. 25; ex-div Aug. 25. * See WLK Dividend Scorecard, Yield Chart, & Dividend …
WLK
main company
Sharemaestro market context
Price below Trend Line
52 weeks -10.5%
Mercury Systems (MRCY) Q2 Earnings Report Preview: What To Look For
Mercury Systems (MRCY) Q2 Earnings Report Preview: What To Look For Aerospace and defense company Mercury Systems (NASDAQ:MRCY) will be reporting results this Tuesday afternoon. Here's what to look for. Mercury Systems beat analysts' revenue expectations last quarter, reporting revenues of $235.8 million, up …
MRCY
main company
Sharemaestro market context
Trend signal active
52 weeks +66.3% · Next-week setup positive 55.4%
Permian Basin Royalty Trust (NYSE:PBT): Why Is Energy Income in Focus Today?
Permian Basin Royalty Trust (NYSE:PBT) is under scrutiny as an energy income vehicle, with its latest update prompting an examination of how well its energy income is supported by operational execution rather than general market sentiment. The article emphasizes that for royalty trusts, cash …
PBT
main company
Sharemaestro market context
Trend signal active
52 weeks +102.2% · Next-week setup positive 65.5%
Why Strategy (MSTR) Shares Are Trading Lower Today
Why Strategy (MSTR) Shares Are Trading Lower Today What Happened? Shares of bitcoin development company Strategy (NASDAQ:MSTR) fell 3.5% in the afternoon session after index provider MSCI proposed removing the company from its Global Investable Market Indexes, compounding concerns over recent sales of its …
MSTR
main company
Sharemaestro market context
Price below Trend Line
52 weeks -74.0% · Next-week setup negative 44.5%
RKLB Stock Rises Overnight: Rocket Lab’s First 8 Satellites From $143M Globalstar Deal Reach Orbit
Rocket Lab's stock (RKLB) rose overnight after the company confirmed that the first eight satellites built under its $143 million contract with MDA Space successfully reached orbit. These satellites, part of a 17-platform deal, will support Globalstar’s direct-to-device communications and IoT services. The successful …
GSAT
main company
Sharemaestro market context
Trend signal active
52 weeks +208.6%
Veeva’s 52% quarter rebuilds the recovery, but light volume and weak Relative Strength keep the signal mixed
Veeva Systems added 5.8% in the latest week and now trades 33.9% above its weekly Trend Line, yet participation remains below average and Relative Strength has not turned positive.
VEEV
main company
Sharemaestro market context
Trend signal started
52 weeks -16.2%
350 Patients Have Been Treated—Mesoblast’s Pain Data Come Next
Mesoblast (MESO) has completed patient treatment in its pivotal Phase 3 trial (MSB-DR004) for chronic low back pain associated with degenerative disc disease, treating 350 patients. The trial evaluates rexlemestrocel-L and targets a primary endpoint of durable pain reduction at 12 months. Top-line results …
MESO
main company
Sharemaestro market context
Price above Trend Line
52 weeks -1.4%
Mesoblast completes patient treatment in phase 3 back pain trial By Investing.com
Mesoblast Limited has completed patient treatment in its phase 3 trial for rexlemestrocel-L, aimed at chronic low back pain associated with degenerative disc disease. The trial enrolled 350 patients and seeks to confirm durable pain reduction as its primary endpoint, with top-line results anticipated …
MESO
main company
Sharemaestro market context
Price above Trend Line
52 weeks -1.4%
Mesoblast Achieves Major Milestone in Pivotal Phase 3 Chronic Low Back Pain Trial
Mesoblast Limited has completed patient treatment in its pivotal Phase 3 trial for chronic low back pain, with 350 patients receiving rexlemestrocel-L or a sham injection. This milestone moves the company closer to potential market entry for its allogeneic cellular medicine, which has RMAT …
MESO
main company
Sharemaestro market context
Price above Trend Line
52 weeks -1.4%
Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain
Mesoblast Limited NEW YORK, Aug. 16, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has completed patient treatment in the MSB-DR004 pivotal randomized controlled Phase 3 trial of rexlemestrocel-L for chronic …
MSB
main company
Sharemaestro market context
Price above Trend Line
52 weeks -7.1%